The Importance of Being Effective: Nesiritide, Ularitide, and why the FDA matters
Today’s article marks the ending of one of the better parables in medicine. It’s the story of a drug that seemed like a really good idea, moved the needle on a lot of surrogate endpoints, and ultimately proved to be ineffective for improving any outcome that might actually be important to patients. It’s the story of nesiritide, recombinant […]